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Conclusion Renal biopsy is strongly recommended for 
T2D patients to distinguish DN, NDRD and NDRD super-
imposed on DN, especially in patients with no signs of DR. 
This approach may help in early diagnosis and treatment 
of NDRD and improve renal outcomes in northeastern Chi-
nese T2D patients.
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Introduction
With the rising prevalence of diabetes mellitus (DM), dia-
betic nephropathy (DN) is now the most common cause of 
end stage-renal disease (ESRD) worldwide [1]. The condi-
tion imposes a heavy economic burden on the healthcare 
system in China [2]. Type 2 diabetes is associated with 
more heterogeneous renal lesions than those in type 1 dia-
betes [2–5]. Moreover, non-diabetic renal disease such as 
IgA nephropathy (IgAN), membranous nephropathy (MN) 
and mesangioproliferative glomerulonephritis (MPGN) 
may coexist with DN. Differentiation between DN and 
non-diabetic renal disease (NDRD) may not be possible 
without renal biopsy.
DN is typically irreversible, while NDRDs may be ame-
nable to cure with early diagnosis and treatment; therefore, 
management and prognosis of NDRD and DN are quite 
different. Identification of NDRD with renal biopsy may 
help guide specific alteration in treatment and, thereby, 
improve prognosis [6, 7]. The indications for renal biopsy 
in type 2 diabetic patients with NDRD include a recent his-
tory of DM, lower HbA1c levels, and normal blood pres-
sure (BP), absence of DR, rapid decline in renal function, 
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Objective To investigate the clinical and histopathologi-
cal features of non-diabetic renal disease (NDRD) super-
imposed on diabetic nephropathy (DN) in northeastern 
Chinese patients with type 2 diabetes mellitus (T2D), and 
compare the changes with those of pure DN and isolated 
NDRD.
Methods Single-center retrospective analysis based on 
medical records of 273 patients (172 men, mean age: 
51.1 ± 12.4 years) with T2D who underwent renal biopsy 
between February 2000 and October 2015. All patients 
were diagnosed as cases of pure DN, isolated NDRD or 
NDRD superimposed on DN.
Results Out of the 273 T2D patients, 68 (24.9 %) had DN, 
175 (64.1 %) had NDRD, and 30 (11.0 %) had NDRD 
superimposed on DN. Idiopathic membranous nephropathy 
(IMN, 29.7 %) was the most common NDRD followed by 
IgA nephropathy (IgAN, 22.9 %), and hypertensive renal 
arteriolar sclerosis was the most common lesion in patients 
diagnosed as NDRD superimposed on DN. Patients with 
NDRD had a shorter duration of diabetes and lower fre-
quencies of diabetic retinopathy (DR, 6.9 %) and renal 
failure (28.0 %), which is consistent with higher estimated 
glomerular filtration rates (eGFR) and lower systolic blood 
pressure (SBP). No significant between-group differences 
were observed with respect to proteinuria and hematuria.
 * Guangdong Sun 
 sungd@jlu.edu.cn
1 The Department of Nephrology, Second Hospital of Jilin 
University, Changchun 130041, Jilin, China
2 The Department of Endocrinology, 208th Hospital of PLA, 
Changchun, China
1692 Int Urol Nephrol (2016) 48:1691–1698
1 3
increasing proteinuria, active urine sediment or acute onset 
of nephrotic syndrome (NS) [6, 8, 9].
Occurrence of NDRD in type 2 diabetic patients has 
been increasingly documented in recent years [10–12]; 
prevalence of NDRD shows considerable regional varia-
tions worldwide [2, 6, 13]. The estimated prevalence of 
NDRD among Chinese type 2 diabetic patients is between 
13.4 and 82.9 % [14–18]. The global prevalence of NDRD 
superimposed on DN is believed to be less than 50 % [2], 
yet the prevalence of NDRD combined with DN in north-
eastern China is not clear.
In this retrospective, single-center study, we assessed the 
prevalence of DN alone, isolated NDRD, and NDRD super-
imposed on DN in type 2 diabetic patients. Detailed analy-
sis of clinical and histopathological features of NDRD with 
or without DN in T2D patients is presented to characterize 
the different nature of NDRD in northeastern China.
Materials and methods
Patients
The present study was conducted in the Department of 
Nephrology, Second Hospital of Jilin University, in north-
eastern China. Of the 4830 patients who underwent renal 
biopsy from February 2000 to October 2015, 311 type 2 
diabetic patients were identified based on the diagnostic 
criteria of the American Diabetic Association [19]. After 
exclusion of patients with malignancies and those with 
history of kidney transplantation and secondary DM, 273 
patients for whom sufficient clinical and laboratory data 
were available were enrolled in this study. The indications 
for renal biopsy included unexplained rapid increase in 
proteinuria or decline in renal function, persistent hematu-
ria of glomerular origin, acute onset of NS, renal involve-
ment in the absence of DR, and patients with recent history 
of DM. The study protocol was approved by the Human 
Ethics Review Committee at the Second Hospital of Jilin 
University; written informed consent was obtained from all 
patients prior to renal biopsy.
Data collection
Data on the following demographic and clinical variables 
were collected at, or close to the time of renal biopsy: age, 
sex, duration of DM, presence of DR, hypertension, dyslip-
idemia, NS, renal failure, proteinuria and hematuria, body 
mass index (BMI), blood pressure, kidney size (kidneys 
mean maximal longitudinal axis on abdominal ultrasonog-
raphy), and treatment history with insulin and/or renin–
angiotensin–aldosterone system (RAAS) blockade.
Data on following laboratory parameters were collected: 
hemoglobin, serum albumin, creatinine and total choles-
terol levels, glycated hemoglobin (HbA1c), and 24-h urine 
protein excretion. Viral markers (HBsAg and anti-hepatitis 
C virus or HIV) were investigated in all cases. Estimated 
glomerular filtration rate (eGFR in mL/min/1.73 m2) was 
calculated from serum creatinine level using the Modified 
Diet in Renal Disease (MDRD) study equation [37].
Proteinuria was defined as >0.3 g/24 h. NS was 
described as proteinuria (>3.5 g/24 h) accompanied 
by hypoalbuminemia (<30 g/L), edema, and hyperlipi-
demia. Hematuria was defined as >3 red blood cells per 
high-power field on urine examination. Renal failure was 
defined as serum creatinine >178 μmol/L. Hypertension 
was defined as a systolic BP > 140 mmHg and/or diastolic 
BP > 90 mmHg.
Renal biopsy
The preferred site for renal biopsy was the lateral aspect 
of the lower pole of the left kidney under ultrasound 
guidance with the patient in the prone position. An auto-
mated biopsy gun and a 16- or 18-gauge needle was used 
to ensure the biopsy sample contained a minimum of ten 
glomeruli. Renal biopsy specimens were prepared accord-
ing to standard methods for light microscopy and immu-
nofluorescence; electron microscopy was not routinely 
performed. For light microscopy, hematoxylin and eosin 
(HE) staining, periodic acid-Schiff’s reagent (PAS) stain-
ing, periodic Schiff-methenamine (PASM) staining, and 
Masson’s trichrome solution (Masson) staining were per-
formed. In certain cases, Congo red and methyl violet 
staining were also done. Immunofluorescent staining for 
IgA, IgG, IgM, C3, C4, C1q, Fib, and κ/λ light chains was 
conducted [20]. All pathological diagnoses were made 
by the same pathologist at the Second Hospital of Jilin 
University.
Pathological diagnostic criteria
DN was diagnosed based on the presence of diffuse or 
nodular glomerulosclerosis, mesangial (nodular or diffuse) 
widening, glomerular hypertrophy, glomerular capillary 
wall thickening, evidence of exudative lesions including 
fibrin caps, capsular drops, or hyaline thrombi. The diag-
nosis of various NDRD was made on the basis of charac-
teristic features on light microscopy examinations in the 
absence of histological features of DN.
All patients were divided into three groups based on 
the biopsy findings: pure DN group (DN), isolated NDRD 
group (NDRD), and NDRD superimposed on DN group 
(DN + DNRD).
1693Int Urol Nephrol (2016) 48:1691–1698 
1 3
Statistical analysis
Statistical analyses were performed using PRISM software 
(Graph Pad, San Diego, CA). Quantitative data on variables 
with a normal distribution are presented as mean ± stand-
ard deviation (SD); those with a skewed distribution are 
expressed as median (range); categorical variables were 
presented as frequencies and percentages [n (%)]. Differ-
ences between groups were assessed with t test or analysis 
of variance (ANOVA) for continuous variables. Values of 
P < 0.05 were regarded as statistically significant.
Results
Demographic and clinical characteristics
Out of a total of 4830 Chinese patients who underwent 
renal biopsy, 273 patients with T2D were included in the 
present study. As shown in Fig. 1, the number of T2D 
patients undergoing renal biopsy has increased over the last 
15 years. Out of 273 patients, 68 patients (24.9 %) had a 
pathological diagnosis of DN, 175 (64.1 %) had isolated 
NDRD, and 30 (11.0 %) had NDRD combined with DN 
(Table 1).
The study population included 172 men and 101 
women (male to female ratio 1.70); the mean age was 
51.1 ± 12.4 years (range 22–8 years). Table 1 shows gen-
eral characteristics of the study population. Duration of 
DM showed much variability (range 1–487 months). DR 
was present in 37 patients (13.6 %). A majority of patients 
had proteinuria and hematuria (261 cases, 95.6 % and 
188 cases, 68.9 %, respectively). 77 patients (28.2 %) had 
NS; 42 patients (15.4 %) had renal failure; 115 patients 
(42.1 %) had hypertension, and 188 patients (68.9 %) had 
dyslipidemia.
Mean 24-h urine protein excretion was 4.81 ± 4.16 g 
(range 0.3–28.2). 110 patients (40.3 %) received insulin 
treatment; 113 patients (41.4 %) underwent RAAS block-
ade therapy at the time of renal biopsy.
Pathological types of NDRD in T2D patients with or 
without DN
Primary glomerulonephritis (GN) was more common than 
secondary GN among patients with NDRD. As shown in 
Table 2, membranous nephropathy (MN) was the most 
common type of primary NDRD lesion (52 [29.7 %] 
patients); the second most common primary NDRD diag-
nosis was IgAN (40 [22.9 %] patients); other less common 
primary NDRD lesions were MPGN (14 patients), mini-
mal change disease (MCD) (6 patients), crescentic GN (4 
patients), and focal segmental glomerulosclerosis (FSGS) 
(3 patients). Interstitial nephritis (IN) accounted for 5.7 % 
of all cases. Lupus nephritis (LN) was the most common 
secondary NDRD lesion (9 [5.1 %] patients), and HBV-
associated glomerulonephritis was the second common sec-
ondary NDRD lesion (8 patients); the other less common 
secondary lesions of NDRD included hypertensive renal 
arteriolar sclerosis (6 patients), ANCA-associated vasculitis 
(AAV) (5 patients), amyloidosis and TMA were observed 
in 4 patients each, and Henoch-Schonlein purpura, 
Fig. 1  Number of type 2 diabetic patients who underwent renal 
biopsy between 2000 and 2015. DN diabetic nephropathy, NDRD 
non-diabetic renal disease, DN + NDRD NDRD superimposed on 
DN
Table 1  Baseline characteristics of 273 type 2 diabetic patients at the 
time of renal biopsy
NDRD non-diabetic renal disease, DN diabetic nephropathy, 
DN + NDRD NDRD superimposed on DN, RAAS renin–angiotensin–
aldosterone system, SD standard deviation
Variables Results
Age at biopsy (years) mean ± SD (range) 51.1 ± 12.4 (22–82)
Sex (male/female) (172/101)
Duration of DM (months) 52.0 ± 68.9 (1–487)
Insulin treatment (yes, %) 110 (40.3 %)
Diabetic retinopathy (yes, %) 37 (13.6 %)
Nephrotic syndrome (yes, %) 77 (28.2 %)
Renal failure (yes, %) 42 (15.4 %)
Hypertension (yes, %) 115 (42.1 %)
Dyslipidemia (yes, %) 188 (68.9 %)
RAAS blockade therapy (yes, %) 113 (41.4 %)
Body mass index (kg/m2) 25.9 ± 4.1 (16–41.1)
24 h-urinary protein (g) 4.81 ± 4.16 (0.3–28.2)
Proteinuria (%) 261 (95.6 %)
Hematuria (%) 188 (68.9 %)
Pathological diagnosis
Diabetic nephropathy (DN) 68 (24.9 %)
Non-diabetic renal disease (NDRD) 175 (64.1 %)
NDRD superimposed on DN 30 (11.0 %)
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lipoprotein glomerulopathy, acute tubular necrosis (ATN) 
in 1 patient each.
The most common NDRD combined with DN was 
hypertensive renal arteriolar sclerosis (19 patients), 
MN was the second common lesion (6 patients), TMA 
was noted in 2 cases, and the other NDRD in this group 
included IgAN, AAV and interstitial nephritis (one patient 
each).
Comparison of clinical and laboratory data
Table 3 shows the baseline patient demographic, clini-
cal, and laboratory parameters. No significant between-
group differences were observed with respect to age, 
sex, incidence of proteinuria and hematuria, BMI, serum 
creatinine, serum albumin, total cholesterol, HbA1c lev-
els, and kidney long axis. A statistically significant dif-
ference was observed in baseline SBP and hemoglobin 
between the groups. The NDRD group showed a lower 
tendency for development of renal failure in as com-
pared to DN + NDRD group. Patients in the pure DN and 
DN + NDRD groups had a longer duration of DM at the 
time of biopsy as compared to those in the isolated NDRD 
group; this difference was especially prominent in the sub-
group of patients who had >120-month-long history of 
DM. Insulin treatment was similar in all the three groups. 
Over 23 % patients in the DN + NDRD group suffered 
from DR, while only 6.9 % patients in the isolated NDRD 
group had DR.
The rate of baseline heavy proteinuria (>3.5 g) was 
significantly higher in patients in the pure DN and 
DN + NDRD groups, as compared to those in the isolated 
NDRD group. On the contrary, the rate of severe hematu-
ria (Urine RBC > 20/HP) was significantly higher in the 
NDRD group as compared to that in the DN + NDRD 
group. No significant difference in eGFR levels was 
observed between the three groups. No significant between-
group differences were observed with respect to results of 
serological tests for systemic diseases including hepatitis 
B surface antigen or hepatitis C virus antibodies, and HIV 
(Table 4). 
Discussion
We assessed the clinical and pathological characteristics 
of DN, NDRD, and NDRD superimposed on DN in type 2 
diabetic patients in a single medical center of northeastern 
China; the relationship between clinical or laboratory data 
and renal pathological characteristics is assessed.
The number of renal biopsy performed in T2D patients 
of northeastern China is increasing year by year. Renal 
biopsies revealed that 75 % cases had NDRD among those 
tested; this finding is in the range of other reports (17–
85 %) [6, 12, 14, 15, 17, 18, 21–26] and a high incidence 
of NDRD complicating DN (11.0 %). A variety of renal 
lesions can occur in T2D patients, the most common pri-
mary pathological types in NDRD group was MN (29.7 %), 
Table 2  Pathological diagnosis of NDRD, with or without DN in type 2 diabetic patients
NDRD non-diabetic renal disease, DN diabetic nephropathy, DN + NDRD NDRD superimposed on DN, IgA Immunoglobulin A, HBV hepatitis 
B virus, ANCA anti-neutrophil cytoplasmic antibody
Pathologic diagnosis based on renal biopsy NDRD (N = 175) DN + NDRD (N = 30) Total (N = 205)
Membranous nephropathy 52 (29.7) 6 (20) 58 (28.3)
IgA nephropathy 40 (22.9) 1 (3.3) 41 (20)
Mesangioproliferative glomerulonephritis (MPGN) 14 (8.0) 0 14 (6.8)
Minimal change disease 6 (3.4) 0 6 (2.9)
Crescentic glomerulonephritis 4 (2.3) 0 4 (2.0)
Focal segmental glomerulosclerosis 3 (1.7) 0 3 (1.5)
Interstitial nephritis 10 (5.7) 1 (3.3) 11 (5.4)
Lupus nephritis 9 (5.1) 0 9 (4.4)
HBV-associated glomerulonephritis 8 (4.6) 0 8 (3.9)
Hypertensive renal arteriolar sclerosis 6 (3.4) 19 (63.3) 25 (12.2)
ANCA-associated vasculitis 5 (2.9) 1 (3.3) 6 (2.9)
Thrombotic microangiopathy (TMA) 4 (2.3) 2 (6.7) 6 (2.9)
Amyloidosis 4 (2.3) 0 4 (2.0)
Henoch-Schonlein purpura 1 (0.6) 0 1 (0.5)
Lipoprotein glomerulopathy 1 (0.6) 0 1 (0.5)
Acute tubular necrosis 1 (0.6) 0 1 (0.5)
Others 7 (3.9) 0 7 (3.3)
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followed by IgAN (22.9 %), and the most secondary patho-
logic type was LN (5.1 %) in this group. This finding is con-
sistent with Asian results reported earlier [6, 13, 27]. In the 
DN + NDRD group, all patients had pathologic hallmarks 
of DN and the most common NDRD lesion was hyperten-
sive renal arteriolar sclerosis (63.3 % of all cases) followed 
by MN (20 %). Overall, the common lesions in NDRD and 
DN + NDRD groups were MN (28.3 %), IgAN (20 %), 
hypertensive renal arteriolar sclerosis (12.2 %), MPGN 
(6.8 %), and interstitial nephritis. Our findings differ from 
those reported earlier in southeastern Asia, in which IgAN 
was the most common NDRD (up to 65 %) [6, 21, 22, 26]. 
In contrast, FSGS have been proven to be the most com-
mon pathological type in USA [28], New Zealand [9], and 
Croatia [29], while AIN was the most prevalent pathological 
type in India, Taiwan, and Malaysia [6, 25, 26, 30]. A study 
showed hypertensive renal damage to be the most common 
pathology in China [18], and IgAN is the most common 
lesion in NDRD superimposed on DN [2, 17] in another 
medical center. The disease spectrum of NDRD with or 
without DN in northeastern China may differ from that in 
other parts of the world. Hereditary and racial predisposi-
tion to different glomerulopathies, plus different eligibility 
criteria for renal biopsy in T2D patients, may have contrib-
uted to the variability in the reported findings.
Duration of DM at the time of renal biopsy was reported 
to be shorter among patients with NDRD as compared to 
that in patients with DN superimposed on NDRD, which 
was broadly accepted as one of the hallmarks of NDRD in 
a previous literature review. Our results are in agreement 
with those of previous studies [6–8]. 40.3 % of the entire 
study population received insulin treatment.
Table 3  Comparison of demographic, clinical characteristics, and laboratory data of diabetic patients by study group (N = 273)
DN diabetic nephropathy, NDRD non-diabetic renal disease, DN + NDRD NDRD superimposed on DN, HbA1c glycated hemoglobin
* P < 0.05 for comparison of NDRD versus DN subgroups & P < 0.05 for comparison of DN + NDRD versus NDRD subgroups
Parameters DN (N = 68) NDRD (N = 175) DN + NDRD (N = 30)
Age at biopsy (years) 50.8 ± 10.3 50.6 ± 12.9 54.9 ± 13.4
Sex (male/female) 44/24 111/64 17/13
Duration of DM (months) 87.1 ± 73.2 (1–243.3) 32.7 ± 52.1 (1–396)* 89.3 ± 98.6 (1–486.6)&
 <12 months 13 (19.1 %) 88 (50.3 %) 5 (16.7 %)
 12–60 months 17 (25 %) 50 (28.6 %) 7 (23.3 %)
 61–120 months 11 (16.2 %) 23 (13.1 %) 8 (26.7 %)
 >120 months 27 (39.7 %) 14 (8.0 %) 10 (33.3 %)
Insulin treatment (yes, %) 35 (51.5 %) 55 (31.4 %) 20 (66.7 %)
Diabetic retinopathy (yes, %) 18 (26.5 %) 12 (6.9 %) 7 (23.3 %)
Proteinuria (yes, %) 66 (97.1 %) 165 (94.3 %) 30 (100 %)
Hematuria (yes, %) 51 (80.9 %) 116 (66.3 %) 21 (70.0 %)
Body mass index (kg/m2) 25.2 ± 3.2 (17.3–33.3) 26.2 ± 4.4 (16–41.1) 25.9 ± 3.5 (19.5–33.0)
 <18 2 (2.9 %) 5 (2.9 %) 0 (0.0 %)
 18–25 30 (44.1 %) 60 (34.3 %) 8 (26.7 %)
 >25 36 (53.0 %) 110 (62.8 %) 22 (73.3 %)
eGFR at Biopsy (mL/min/1.73 m2) 55.7 ± 3.3 74.9 ± 3.0* 61.1 ± 6.9
Renal failure (yes, %) 29 (42.6 %) 49 (28.0 %)* 13 (43.3 %)
Dyslipidemia (yes, %) 49 (72.1 %) 118 (67.4 %) 21 (70.0 %)
Hypertension (yes, %) 40 (58.8 %) 45 (25.7 %) 30 (100 %)
Systolic BP (mmHg) 153 ± 22 (120–230) 137 ± 19 (100–230)* 153 ± 20 (120–220)&
Diastolic BP (mmHg) 88 ± 11 (70–120) 87 ± 13 (60–150) 91 ± 12 (60–118)
Kidney long axis (cm) 10.9 ± 1.0 (9.4–13.8) 10.8 ± 0.9 (9.0–13.4) 10.9 ± 0.8 (9.7–12.9)
Laboratory findings
 Hemoglobin (g/L) 117 ± 22 (71–172) 133 ± 29 (30–186)* 120 ± 25 (58–174)&
 Serum creatinine (μmol/L) 149.8 ± 159.2 (46.2–1154.3) 139.0 ± 158.4 (26.0–1202.2) 137.1 ± 93.0 (44.0–395.2)
 Serum albumin (g/L) 30.8 ± 7.8 (15.3–51.9) 32.7 ± 9.0 (13.1–49.1) 31.6 ± 9.2 (20.0–51.6)
 Total cholesterol (mmol/L) 6.6 ± 1.8 (3.4–13.1) 6.9 ± 3.1 (1.8–20.1) 7.1 ± 2.8 (3.2–15.0)
 HbA1c (%) 7.4 ± 2.4 (4.4–17.7) 6.9 ± 1.9 (4.6–16.2) 6.7 ± 1.3 (3.8–9.7)
 Proteinuria (g/d) 5.26 ± 3.60 (0.15–19) 4.41 ± 4.33 (0.13–28.2) 6.12 ± 4.12 (0.35–15.62)
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In this study, the NDRD patients had a higher rate 
of baseline proteinuria (>90 %) and a lower rate of NS 
(42.3 %); however, the incidence rates in NDRD group 
did not differ from other groups, which is contrary to a 
previous study [7], where the degree of proteinuria in 
DN patients was higher compared to that in patients with 
NDRD. Likewise, the lack of between-group differences 
with respect to hematuria in our study (about 70 %) is 
not consistent with earlier studies which found degree of 
hematuria helped to distinguish NDRD from DN [6, 27, 
30]. However, on subgroup analysis by degree of hematu-
ria, more NDRD patients had urine RBC ˃ 20/HP although 
the difference was not statistically significant. Further, in a 
newly published report, detection of dysmorphic erythro-
cytes was a stronger correlation of NDRD in T2D as com-
pared to hematuria [31]. It may be better to replace hema-
turia to distinguish NDRD from DN in the future. In this 
study, NDRD group had a higher baseline level of eGFR 
than DN ± NDRD group, which is consistent with the 
lower rate of renal failure in NDRD group reported earlier 
[30].
No significant differences were observed with respect 
to dyslipidemia between DN, NDRD, and DN + NDRD 
groups; the average total cholesterol levels in patients with 
DN did not differ from that in other groups, which is in 
agreement with previous studies [13, 21, 32, 33]. Another 
finding in the present study was the lack of difference in 
BMI between the 3 groups, which is in accordance with 
the results of several studies [26, 29], while two conflicting 
results have been reported in this respect in the Chinese 
context [32, 34]. Large prospective studies may help to 
understand the BMI change in Chinese T2D patients with 
NDRD ± DN in the future.
The frequency of hypertension in the NDRD group (45 
cases, 25.7 %) was significantly lower as compared to that 
in the DN ± NDRD group, which is consistent with ear-
lier reports [8, 13, 21, 29, 34]. This suggests that absence 
of hypertension in DM is one of the diagnostic features of 
NDRD, which may be linked to high dietary intake of salt 
northeastern China [35, 36]. 41.4 % patients were receiv-
ing RAAS blockade therapy at the time of renal biopsy; the 
proportion of patients receiving RAAS blockade is lower 
than that reported from previous two studies [26, 37]. This 
suggests that blood pressure control may be preventing pro-
gression of renal disease.
The retrospective study design and small sample size 
are foremost limitations of our study. Of note, selection 
bias is inevitable in any biopsy-based study. In general, our 
results can be applicable to T2D patients who were will-
ing to undergo renal biopsy, the likelihood of which is rela-
tively low in the Jilin Province (<10 %) due to the invasive 
nature of the investigation and, to some extent, reluctance 
on the part of nephrologists to perform renal biopsy owing 
to the associated risk of complications. The present study 
involved T2D patients only in one medical center of Jilin 
province, which could result in sampling bias. The patho-
logical diagnoses in the patients included in this study 
were made by the same pathologist, which could have 
Table 4  Reported indicators 
and significant laboratory values 
in diabetic patients undergoing 
renal biopsy
DN diabetic nephropathy, NDRD non-diabetic renal disease, DN + NDRD NDRD superimposed on DN, 
HPF high-power field, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, HIV human immunode-
ficiency virus
Variables DN (N = 68) NDRD (N = 175) DN + NDRD (N = 30)
Proteinuria (g/day)
 Data not available 1 (1.5) 3 (1.7) 0 (0)
 <0.5 1 (1.5) 17 (9.7) 2 (6.7)
 0.5–3.5 23 (33.8) 81 (46.3) 6 (20.0)
 >3.5 43 (63.2) 74 (42.3) 22 (73.3)
Hematuria
 Data not available 3 (4.4) 1 (0.6) 1 (3.3)
 Urine RBC > 3/HPF 51 (75) 117 (66.9) 21 (70)
 Urine RBC > 10/HPF 21 (30.9) 61 (34.9) 11 (36.7)
 Urine RBC > 20/HPF 10 (14.7) 48 (27.4) 7 (10.3)
Serum creatinine (μmol/L)
 Data not available 0 (0.0) 1 (0.6) 0 (0.0)
 <178 57 (83.9) 148 (84.5) 25 (83.3)
 ≥178 11 (16.1) 26 (14.9) 5 (16.7)
Any positive serologic test
 (+) HBsAg or HCV antibody 18 (26.5) 32 (18.3) 5 (16.7)
 (+) HIV 0 (0.0) 0 (0.0) 0 (0.0)
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introduced an element of subjectivity. DR has been classi-
cally regarded as the indicator of DN, but the reported DR 
rate was only 15.4 %, which is another shortcoming that 
limits the generalizability of our findings. Previous studies 
have shown an association between low serum complement 
levels (C3/C4) and NDRD [7]; however, due to lack of data 
we did not assess this association. Such limitations indicate 
the need for prospective studies to understand the natural 
history of NDRD superimposed on DN in China.
In this study, 11.0 % of northeastern Chinese T2D 
patients had NDRD superimposed on DN. The most com-
mon pathological diagnosis was hypertensive renal arteri-
olar sclerosis. Patients with isolated NDRD tended to have 
a shorter history of DM and lack of DR. Larger, multi-
center randomized prospective studies are therefore needed 
to confirm preliminary changes in T2D patients in order to 
distinguish NDRD from NDRD superimposed on DN at an 
early stage, which will help in initiating specific treatment, 
and thereby, improving kidney survival and reducing the 
incidence of chronic kidney disease (CKD).
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